eligibility_summary
Adults ≥18 with histologically confirmed invasive breast cancer: TNBC, HER2+, or high‑risk ER+ (≥2 of: grade 3, age ≤50, ER Allred <6, Ki‑67 ≥30%). Tumor ≥2 cm, bilateral allowed with an index lesion and same regimen. ECOG 0–1, LVEF ≥ LLN, adequate organ function. Exclude: stage IV, inflammatory, pregnant/lactating, prior anthracyclines or prior therapy/excisional biopsy/lumpectomy, significant cardiac disease, HIV/HBV/HCV, recent other cancers, or serious comorbid/psychosocial issues.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II neoadjuvant study using standard-of-care regimens to correlate early clinical response with pathologic complete response. Regimens: TNBC (>5 cm): paclitaxel + carboplatin ± pembrolizumab, then doxorubicin + cyclophosphamide (AC) ± pembrolizumab, TNBC (<5 cm): paclitaxel then AC, HER2+: paclitaxel + trastuzumab + pertuzumab (or SC PHESGO), then AC, High-risk HR+: paclitaxel + carboplatin, then AC. Mechanisms/types: paclitaxel (taxane, microtubule stabilizer → mitotic arrest), carboplatin (platinum DNA crosslinker), doxorubicin (anthracycline DNA intercalator/topoisomerase II inhibitor/ROS), cyclophosphamide (alkylating DNA crosslinker), pembrolizumab (anti-PD-1 mAb releasing T-cell inhibition), trastuzumab (anti-HER2 mAb blocking signaling/ADCC), pertuzumab (anti-HER2 mAb blocking dimerization), PHESGO includes hyaluronidase for SC delivery. Targets: HER2/ERBB signaling, PD-1/PD-L1 checkpoint on T cells, microtubules, DNA replication/repair, topoisomerase II.